Kura Oncology, Inc. Common Stock (KURA) Stock
NASDAQ · KURA
10.51
Fundamentals
Market cap
$957.22M
Price / Earnings ratio
-3.3x
Price / Sales ratio
12.5x
Price / Book ratio
19.9x
Return on assets
-43.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Zacks Investment Research
KURA Stock Gains 37.6% in a Month: Here's What You Need to Know
NeutralKURASeptember 1, 2026
Zacks Investment ResearchNeutral
KURA Stock Gains 37.6% in a Month: Here's What You Need to Know
KURA

Zacks Investment Research
Kura Oncology (KURA) Upgraded to Buy: What Does It Mean for the Stock?
NeutralKURAAugust 31, 2026
Zacks Investment ResearchNeutral
Kura Oncology (KURA) Upgraded to Buy: What Does It Mean for the Stock?
KURA

Zacks Investment Research
Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves
NeutralKURAAugust 27, 2026
Zacks Investment ResearchNeutral
Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves
KURA

Stocktwits
KURA Stock Hits Fresh 52-Week High As CEO Buys More Shares — Retail Wonders If Wilson Is Following Moderna CEO’s Playbook
NeutralKURAAugust 25, 2026
StocktwitsNeutral
KURA Stock Hits Fresh 52-Week High As CEO Buys More Shares — Retail Wonders If Wilson Is Following Moderna CEO’s Playbook
KURA
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy2
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
81M53M27M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
886M585M292M0
Revenue to Profit
2025$67.5M
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-278.7M
Net incomeEarnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

Zacks Investment Research
KURA Stock Gains 37.6% in a Month: Here's What You Need to Know
NeutralKURASeptember 1, 2026
Zacks Investment ResearchNeutral
KURA Stock Gains 37.6% in a Month: Here's What You Need to Know
KURA

Zacks Investment Research
Kura Oncology (KURA) Upgraded to Buy: What Does It Mean for the Stock?
NeutralKURAAugust 31, 2026
Zacks Investment ResearchNeutral
Kura Oncology (KURA) Upgraded to Buy: What Does It Mean for the Stock?
KURA

Zacks Investment Research
Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves
NeutralKURAAugust 27, 2026
Zacks Investment ResearchNeutral
Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves
KURA

Stocktwits
KURA Stock Hits Fresh 52-Week High As CEO Buys More Shares — Retail Wonders If Wilson Is Following Moderna CEO’s Playbook
NeutralKURAAugust 25, 2026
StocktwitsNeutral
KURA Stock Hits Fresh 52-Week High As CEO Buys More Shares — Retail Wonders If Wilson Is Following Moderna CEO’s Playbook
KURA

The Motley Fool
Kura Oncology CEO Buys 100,000 Shares for $1.2 Million. Does This Large Buy Bode Well for Shares in 2026?
NeutralKURAAugust 25, 2026
The Motley FoolNeutral
Kura Oncology CEO Buys 100,000 Shares for $1.2 Million. Does This Large Buy Bode Well for Shares in 2026?
KURA

Zacks Investment Research
Kura Oncology (KURA) is a Great Momentum Stock: Should You Buy?
NeutralKURAAugust 19, 2026
Zacks Investment ResearchNeutral
Kura Oncology (KURA) is a Great Momentum Stock: Should You Buy?
KURA

Zacks Investment Research
Does Kura Oncology (KURA) Have the Potential to Rally 178.55% as Wall Street Analysts Expect?
NeutralKURAAugust 18, 2026
Zacks Investment ResearchNeutral
Does Kura Oncology (KURA) Have the Potential to Rally 178.55% as Wall Street Analysts Expect?
KURA

Stocktwits
Why Is KURA Stock Rallying 8% After-Hours?
NeutralKURAAugust 17, 2026
StocktwitsNeutral
Why Is KURA Stock Rallying 8% After-Hours?
KURA

MarketBeat
Kura Oncology Q2 Earnings Call Highlights
NeutralKURAAugust 13, 2026
MarketBeatNeutral
Kura Oncology Q2 Earnings Call Highlights
KURA

Zacks Investment Research
Kura Oncology (KURA) Reports Q2 Loss, Beats Revenue Estimates
NeutralKURAAugust 12, 2026
Zacks Investment ResearchNeutral
Kura Oncology (KURA) Reports Q2 Loss, Beats Revenue Estimates
KURA
About Kura Oncology, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees260
CEODr. Troy Edward Wilson J.D., Ph.D.
IPO DateNov 5, 2015
HeadquartersSan Diego, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Troy Edward Wilson J.D., Ph.D. | Chairman, CEO & President | 1969 |
| Ms. Kathleen Ford | Chief Operating Officer | 1947 |
| Mr. Brian T. Powl M.B.A., M.S. | Chief Commercial Officer | 1974 |
| Mr. Thomas Doyle | Senior Vice President of Finance & Accounting | 1971 |
| Dr. Francis J. Burrows Ph.D. | Chief Scientific Officer | 1962 |
| Mr. Greg Mann | Senior Vice President of Investor Relations & Corporate Affairs | — |
| Ms. Teresa Brophy Bair Esq., J.D. | Chief Legal Officer & Corporate Secretary | 1971 |
| Dr. Roger Bakale Ph.D. | Senior Vice President of Manufacturing & Supply Chain | — |
| Dr. Mollie Leoni M.D. | Chief Medical Officer | 1978 |
| Mr. Samir Vattompadam M.S. | Senior Vice President of Global Program Leadership | — |
Fundamentals
Valuation
Market cap$957.22M
Price-to-sales ratio12.51
Price-to-book value19.95
Price-earnings ratio-3.30
Return on Equity-142.00%
Return on Sales-409.00%
Return on Assets-43.00%
PEG ratio0.00
Earnings Per Share
Earnings Per Share$-3.37
Income Statement
Average volume2,075,695
EBITDA$-291.88M
1 year high (52w)$13.90
1 year low (52w)$7.36
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
2 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$31.00
Est return
188.10%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +0.1 | -14.2 | -18.3 | +4.9 | ||||||||
| 2022 | -4.1 | +15.8 | +0.6 | -14.3 | -12.1 | +35.0 | -17.2 | -7.2 | -9.3 | +18.7 | -1.4 | -20.3 |
| 2023 | +14.7 | -14.2 | +2.3 | -23.8 | +27.6 | -21.6 | -1.5 | -4.0 | -9.3 | -1.7 | +21.0 | +44.4 |
| 2024 | +31.1 | +0.3 | -1.2 | -10.1 | +1.6 | -2.8 | -1.8 | +4.3 | -3.3 | -13.0 | -34.6 | -22.2 |
| 2025 | -8.9 | -6.5 | -9.0 | +2.8 | -12.3 | -8.4 | +8.0 | +31.2 | +11.3 | +11.6 | +24.3 | -9.2 |
| 2026 | -21.5 | +5.6 | -6.3 | +5.9 | +16.3 | +21.3 | -16.4 | +37.6 | -16.5 |



